Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Home
/
Trials
/
NCT00144131
NCT00144131
View on ClinicalTrials.gov
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
PHASE2
Completed
INTERVENTIONAL
Enrollment
750
Participants
Timeline
Start Date
August 31, 2005
Conditions
Anemia
Cancer
Interventions
DRUG
Aranesp®
Sponsors
Lead Sponsor
Amgen
All Listed Sponsors
lead
Amgen
INDUSTRY